Idorsia Plans Significant Presentations at Major Conferences
Idorsia Ltd is set to share compelling insights surrounding their drug aprocitentan at prominent medical gatherings. These important presentations will be made during the upcoming ASN Kidney Week and AHA Scientific Sessions, aimed at enhancing the understanding of resistant hypertension among healthcare professionals.
Key Findings from the PRECISION Study
New research validates that aprocitentan effectively reduces both blood pressure and albuminuria in patients struggling with true resistant hypertension. This group typically includes individuals presenting high cardiovascular risk factors, including the presence of chronic kidney disease. The research underscores aprocitentan's significance in managing these complex health conditions.
Understanding Aprocitentan's Effects
As part of the results from the pivotal Phase 3 PRECISION study, a poster presentation titled “Is Aprocitentan's Effect on Albuminuria Merely Due to Lowered BP? Subgroup Analysis of the PRECISION Trial” will be showcased during the ASN Kidney Week. This analysis will delve into how aprocitentan, when administered alongside at least three antihypertensives, leads to notable reductions in systolic blood pressure and enhances the Urine Albumin-to-Creatinine Ratio (UACR), indicating renal benefits.
Importantly, the findings suggest that the significant drops in blood pressure attributed to aprocitentan alone do not fully account for the observed declines in UACR levels. The research proposes that additional mechanisms may also contribute to the renal-protective properties of this innovative drug.
Educational Symposium Highlights
Expanding its presence, Idorsia will also participate in the AHA Scientific Sessions with an educational symposium entitled ‘The Next Era in the Treatment of Hypertension.’ This session is scheduled for November 9th, and Dr. Michael Bloch will be presenting data that not only underscores the efficacy of aprocitentan but also discusses its implementation in real-world clinical settings.
About Aprocitentan
Aprocitentan stands out as Idorsia’s once-daily oral medication that acts as a dual endothelin receptor antagonist, effectively interrupting the action of ET-1 on ETA and ETB receptors. Initially launched as TRYVIO in the U.S. for the treatment of systemic hypertension in combination with other antihypertensives, it continues to receive positive attention within medical circles. The regulatory approval timelines indicate an affirmative outlook toward its use in resistant hypertension across markets in Europe and beyond.
In the treatment of systemic hypertension, aprocitentan has garnered crucial endorsements, being included in the latest clinical practice guidelines by respected bodies like the American College of Cardiology and the American Heart Association. This acknowledgment exemplifies its importance in tackling hypertension effectively.
Idorsia's Vision and Future
Idorsia’s commitment is to challenge conventional medical narratives and innovate healthcare solutions that resonate with patient needs. Their comprehensive approach focuses on discovering, developing, and bringing transformative medicines to the market through robust in-house research and partnership initiatives.
The company is strategically located in: Basel, Switzerland, a renowned biotech hub fostering impactful medical advancements. Idorsia's ambition is clear: to lead in biopharmaceuticals with a strong scientific foundation, reinforced by talented professionals dedicated to enhancing patient care.
Contact Information
For those interested in further details or inquiries regarding Idorsia’s advancements, the Investor & Media Relations team is available:
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 58 844 10 10
investor.relations@idorsia.com – media.relations@idorsia.com – www.idorsia.com
Frequently Asked Questions
What is Aprocitentan?
Aprocitentan is an innovative dual endothelin receptor antagonist developed by Idorsia, aimed at treating resistant hypertension and improving renal outcomes.
Where will Aprocitentan be presented?
Findings about Aprocitentan will be presented at the ASN Kidney Week and the AHA Scientific Sessions, focusing on its efficacy and safety.
Who is Dr. Michael Bloch?
Dr. Michael Bloch is an Associate Professor in Internal Medicine and will present clinical data regarding aprocitentan at the AHA Symposium.
What are the key benefits of Aprocitentan?
Aprocitentan has been shown to significantly lower blood pressure and albuminuria levels, suggesting potential renal protective effects.
Is Aprocitentan approved in other countries?
Yes, Aprocitentan is approved in various regions, including the European Union as JERAYGO for resistant hypertension and is under review in Canada.
